Skip to main content
Category

News Archive

nhlbi-nih-logo

NHLBI Funding & Research Opportunities and Announcements for September 2, 2016

By News Archive

nhlbi-nih-logo

Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

Notices:

  • Notice of NCCIH’s Participation in PA-16-414 “Innovation Corps (I-Corps) at NIH Program for NIH and CDC Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp)”
    • (NOT-AT-16-003)
    • National Center for Complementary and Integrative Health
  • Notice of Clarification to NHLBI’s Policy Regarding Total Years of Support for K24 Funding 
  • Notice of Technical Assistance Webinars for Human Heredity and Health in Africa (H3Africa) FOAs: RFA-RM-011, RFA-RM-012, RFA-RM-013, RFA-RM-014, RFA-RM-16-015, RFA-RM-016, and RFA-RM-017
  • Notice of New Expiration Date for RFA-RM-16-013 “Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Research Program (U01)”

Requests for Applications: 

  • Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research (R21)
neopenda-logo

Meet The Women Whose Phenomenal Invention Will Save Thousands Of Lives

By News Archive

neopenda-logo

Opinions expressed by Forbes Contributors are their own. Creating a tech invention with global potential is an ambition that many of us harbor but only relatively few are able to actually achieve.

So for the co-creators of a device that monitors newborn baby vital signs and improves their chances of survival in parts of the developing world, the sense of achievement in getting their startup idea off the ground is bolstered further by a feeling of real pride in doing work that could save thousands of lives.

Read More
regenerx-logo

RegeneRx Receives Notice of Intent to Grant Patent for the Treatment of Patients with Multiple Sclerosis in EU

By News Archive

regenerx-logo

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for the treatment of patients with MS. The patent covers use of the Company’s proprietary molecule Thymosin beta 4 (Tβ4) in a composition for treating or reducing deterioration of, injury or damage to tissue due to MS. The patent expiry is January 13, 2026.

Read More
nih-logo

Report: Maryland’s bioscience industry a leader in NIH funding, venture capital investment – fredericknewspost.com

By News Archive

nih-logo

Maryland is a leader in National Institutes of Health funding for biomedical research and in venture capital investment for bioscience-related companies, according to a recent study from the Biotechnology Innovation Organization.

The bioscience industry employs more than 34,000 people in Maryland, and the average annual wage for a bioscience worker in the United States reached $94,543 in 2014, according to the report.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.